Analysts Expect AmerisourceBergen Corp. (ABC) to Post $1.63 Earnings Per Share

Wall Street analysts predict that AmerisourceBergen Corp. (NYSE:ABC) will report earnings of $1.63 per share for the current quarter, according to Zacks. Five analysts have made estimates for AmerisourceBergen’s earnings. The highest EPS estimate is $1.66 and the lowest is $1.60. AmerisourceBergen posted earnings per share of $1.54 in the same quarter last year, which indicates a positive year-over-year growth rate of 5.8%. The company is scheduled to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that AmerisourceBergen will report full-year earnings of $6.81 per share for the current fiscal year, with EPS estimates ranging from $6.72 to $6.90. For the next fiscal year, analysts expect that the company will report earnings of $7.34 per share, with EPS estimates ranging from $7.18 to $7.50. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for AmerisourceBergen.

AmerisourceBergen (NYSE:ABC) last announced its earnings results on Thursday, May 2nd. The company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.15. AmerisourceBergen had a net margin of 0.53% and a return on equity of 46.24%. The company had revenue of $43.32 billion for the quarter, compared to the consensus estimate of $43.44 billion. During the same period in the previous year, the business earned $1.94 EPS. The company’s revenue was up 5.6% on a year-over-year basis.

Several analysts have issued reports on the stock. ValuEngine raised shares of AmerisourceBergen from a “sell” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research raised shares of AmerisourceBergen from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Tuesday, May 14th. Guggenheim assumed coverage on shares of AmerisourceBergen in a research note on Thursday, April 11th. They set a “buy” rating on the stock. Finally, TheStreet cut shares of AmerisourceBergen from a “b” rating to a “c+” rating in a report on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $86.38.

NYSE:ABC traded up $0.25 during trading hours on Wednesday, hitting $80.82. 19,050 shares of the stock traded hands, compared to its average volume of 1,491,051. The company has a quick ratio of 0.56, a current ratio of 0.95 and a debt-to-equity ratio of 1.43. AmerisourceBergen has a fifty-two week low of $69.36 and a fifty-two week high of $94.88. The company has a market cap of $16.85 billion, a P/E ratio of 12.47, a price-to-earnings-growth ratio of 1.51 and a beta of 1.07.

The business also recently declared a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Monday, May 20th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 1.98%. The ex-dividend date of this dividend is Friday, May 17th. AmerisourceBergen’s dividend payout ratio is currently 24.65%.

In related news, CEO Steven H. Collis sold 21,344 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $83.62, for a total value of $1,784,785.28. Following the completion of the sale, the chief executive officer now directly owns 155,923 shares in the company, valued at $13,038,281.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dale Danilewitz sold 5,702 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $77.61, for a total transaction of $442,532.22. Following the completion of the sale, the insider now owns 7,330 shares of the company’s stock, valued at $568,881.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 2,018 shares of company stock worth $156,471 and have sold 40,086 shares worth $3,235,648. Insiders own 27.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc raised its position in shares of AmerisourceBergen by 0.4% during the third quarter. Vanguard Group Inc now owns 16,019,657 shares of the company’s stock valued at $1,477,332,000 after buying an additional 63,935 shares during the last quarter. FMR LLC raised its position in shares of AmerisourceBergen by 51.7% during the fourth quarter. FMR LLC now owns 7,263,899 shares of the company’s stock valued at $540,434,000 after buying an additional 2,474,112 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of AmerisourceBergen by 6,614.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,448,589 shares of the company’s stock valued at $46,000 after buying an additional 3,397,228 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of AmerisourceBergen by 4.9% during the first quarter. Victory Capital Management Inc. now owns 2,523,629 shares of the company’s stock valued at $200,679,000 after buying an additional 116,808 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of AmerisourceBergen by 14.4% during the first quarter. Northern Trust Corp now owns 2,433,611 shares of the company’s stock valued at $193,521,000 after buying an additional 306,161 shares during the last quarter. Institutional investors own 66.73% of the company’s stock.

About AmerisourceBergen

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.

Featured Article: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on AmerisourceBergen (ABC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.